An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.
Phase 4
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Hyperparathyroidism, Parathyroid Neoplasms
Both
Hyperparathyroidism, Parathyroid Neoplasms
Trial Information
An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.
Inclusion Criteria
- Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; *
Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; *
Not have had any type of cancer other than parathyroid carcinoma within the last 5
years.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Changes in serum calcium and PTH
Principal Investigator
MD
Investigator Role:
Study Director
Investigator Affiliation:
Amgen
Authority:
United States: Food and Drug Administration
Study ID:
20000204
NCT ID:
NCT00037518
Start Date:
April 2001
Completion Date:
Related Keywords:
- Hyperparathyroidism
- Parathyroid Neoplasms
- Severe primary hyperparathyroidism
- Parathyroid carcinoma
- Neoplasms
- Hyperparathyroidism
- Parathyroid Neoplasms
- Hyperparathyroidism, Primary
Name | Location |
|---|
